Serina Therapeutics Inc (SER) — Cash Flow-to-Debt Ratio
Serina Therapeutics Inc (SER) has a Cash Flow-to-Debt Ratio of -0.36x as of September 2025, meaning its operating cash flow of $-3.85 Million could theoretically repay 0% of its total liabilities ($10.82 Million) in one year. See cash generation quality of Serina Therapeutics Inc to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Serina Therapeutics Inc Cash Flow-to-Debt Ratio (2016–2024)
Historical debt coverage capacity for Serina Therapeutics Inc across 9 annual periods. Also explore SER shareholders equity momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Serina Therapeutics Inc (2016–2024)
Year-by-year debt coverage analysis for Serina Therapeutics Inc. For market capitalisation and broader financial context, see Serina Therapeutics Inc (SER) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -2.76x | $-17.14 Million | $6.22 Million | ▼ -4494.3% |
| 2023 | -0.06x | $-2.48 Million | $41.26 Million | ▲ +40.6% |
| 2022 | -0.10x | $-2.08 Million | $20.56 Million | ▲ +32.6% |
| 2021 | -0.15x | $-2.25 Million | $15.03 Million | ▲ +82.1% |
| 2020 | -0.84x | $-7.82 Million | $9.32 Million | ▲ +60.2% |
| 2019 | -2.11x | $-10.16 Million | $4.83 Million | ▲ +35.7% |
| 2018 | -3.28x | $-8.00 Million | $2.44 Million | ▲ +31.6% |
| 2017 | -4.79x | $-6.29 Million | $1.31 Million | ▼ -1355.1% |
| 2016 | -0.33x | $-8.43 Million | $25.60 Million | — |